Vyaire Medical is selling its consumables business to SunMed, a manufacturer and distributor of consumable medical devices for anesthesia and respiratory care.
The Vyaire consumables portfolio includes airway management and operative care technology, including brands such as AirLife oxygen therapy, Vital Signs anesthesia circuits, and SuperNO2VA nasal PAP ventilation.
Gaurav Agarwal, CEO of the Chicago, IL-based company, said the divestiture allows Vyaire to focus on its respiratory diagnostics and ventilation businesses and accelerate its strategic growth plans.
“Uniting the industry-leading Vyaire consumables portfolio with SunMed’s compatible suite of products is a win-win for both companies, as well as customers and patients, and will enhance the potential for long-term growth of the combined consumables portfolio," Agarwal said.
Financial terms of the deal were not disclosed.
Vyaire said it will continue to fully manage its consumables business and products until the transaction is finalized, with full support to customers, and will work to ensure continuity for partners and suppliers. The agreement is subject to antitrust regulatory clearance in the United States. The deal is expected to be finalized "in the coming months."
Grand Rapids, MI-based SunMed said the combined business, as a leading manufacturer wholly dedicated to this market, "will be well positioned to enhance innovation, ensure reliable and predictable product supply for customers and be a one-stop source for the highest-quality consumable respiratory and anesthesia medical products to ensure the best outcomes for patients."
“This combination represents an exciting growth opportunity for SunMed that will strengthen our already robust core consumables business and further differentiate our ability to meet our customers’ needs,” said SunMed CEO Hank Struik. “The transaction brings together two like-minded teams who share a deep commitment to quality, reliability, and continuous innovation as trusted partners to healthcare professionals. Vyaire’s respiratory and anesthesia business brings an impressive manufacturing platform, which will add to our already deep North American manufacturing presence, a strong product pipeline with some of the most trusted brands in the market and deep relationships with customers and distributors. This transaction will enable us to deliver even greater innovation, predictability and value for our customers, their practitioners, and their patients – all on an expanded global basis.”